白内障发病机制与防治策略的研究进展  

Advances in pathogenesis and pharmacotherapy of cataract

作　　者：徐靖杰 张颖 姚克 陈祥军 XU JingJie;ZHANG Ying;YAO Ke;CHEN XiangJun(Institute of Translational Medicine,Zhejiang University School of Medicine,Hangzhou 310020,China;Eye Center of the Second Affiliated Hospital,Medical College of Zhejiang University,Hangzhou 310092,China)

机构地区：[1]浙江大学医学院转化医学研究院,杭州310020 [2]浙江大学附属第二医院眼科中心,杭州310092

出　　处：《中国科学：生命科学》2022年第12期1807-1814,共8页Scientia Sinica(Vitae)

基　　金：国家自然科学基金(批准号:31872724,81900837,82070939);浙江省科技厅基金(批准号:2019C03091);浙江省科技厅重点研发计划(No.2019C03091)资助;浙江省自然科学基金(批准号:LR21H120001)。

摘　　要：白内障是全球首位致盲性眼病.随着人口老龄化加剧,白内障将导致巨大的社会和经济负担.目前,手术治疗作为唯一的治愈手段,仍存在个体疗效差异、手术禁忌症、并发症及经济负担等诸多局限性,已不能满足当前社会需求.因此,研究白内障发病机制,找寻白内障潜在的治疗药物一直是研究的热点.本文基于团队目前的工作内容,从白内障发病机制、白内障模型进展及白内障防治药物的开发筛选等方面对白内障的发病机制及防治策略进行综述.Cataract is the leading cause of vision impairment worldwide.As the population ages,the prevalence of cataract will increase rapidly,which has caused a substantial social and economic burden.Although cataract surgery is effective,it still suffers from complications and high costs and could not meet the increasing surgery demand.Therefore,pharmacological treatment for cataracts is cheaper and more readily available for patients.Therefore,research on the pathogenesis of cataract and exploring potential therapeutic drugs for cataract have always been a research hotspot for years.Based on our team’s current work,this article summarizes the pathogenesis and pharmacotherapy strategies of cataract from the pathogenesis of cataract,the cataract disease models,and the development of anti-cataract drugs.

关 键 词：白内障 发病机制 药物防治 

分 类 号：R776.1[医药卫生—眼科]